IMUC : Summary for ImmunoCellular Therapeutics, Lt - Yahoo Finance

U.S. Markets open in 2 hrs 35 mins

ImmunoCellular Therapeutics, Ltd. (IMUC)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
2.39+0.03 (+1.27%)
At close: 4:02PM EST
People also watch
NWBOGALERNNCURMSTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.36
Open2.35
Bid0.00 x
Ask0.00 x
Day's Range2.24 - 2.43
52 Week Range1.83 - 14.80
Volume17,250
Avg. Volume103,036
Market Cap8.27M
Beta0.04
PE Ratio (TTM)-11.38
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Accesswire11 days ago

    Latest Reports on ImmunoCellular Therapeutics and Neuralstem as Biotech Industry Scrutiny Grows after President Trump's Comments

    NEW YORK, NY / ACCESSWIRE / January 12, 2017 / Biotech and Healthcare stocks were slammed Wednesday as President Donald Trump made some critical remarks against the industries at his first news conference ...

  • PR Newswirelast month

    ImmunoCellular Therapeutics Announces Management Changes

    LOS ANGELES, Dec. 14, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced today that the Board of Directors has appointed Anthony Gringeri, PhD, as Chief Executive Officer and a member of the Board of Directors. Dr. Gringeri has served as ImmunoCellular's Senior Vice President of Strategic Resources since August 2013, and has led the implementation of the Company's clinical and regulatory strategy for the ICT-107 phase 3 registration trial in newly diagnosed glioblastoma, as well as the ICT-121 phase 1 trial in recurrent glioblastoma. The appointment of Dr. Gringeri follows the decision by Andrew Gengos to resign the position of Chief Executive Officer.

  • PR Newswire2 months ago

    ImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial in Newly Diagnosed Glioblastoma at the Society for Neuro-Oncology Annual Meeting 2016

    LOS ANGELES, Nov. 21, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced the presentation of updated immune monitoring data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma. ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ICT-107 is currently being tested in a phase 3 registration trial in patients with newly diagnosed glioblastoma.